BACKGROUND: Extrapyramidal signs (EPS) may vary across 3 major subtypes of primary progressive aphasia (PPA): progressive nonfluent aphasia (PNFA), semantic dementia (SD), and progressive logopenic aphasia (PLA). METHODS: We reviewed initial neurological examinations from a clinical PPA cohort (PNFA = 49, SD = 26, PLA = 28) to determine the prevalence of specific categories of EPS. RESULTS: The presence of any EPS was more common in PNFA (38.8%) and PLA (35.7%) than in SD (3.8%). The PNFA group exhibited the highest prevalence of bradykinesia (PNFA: 22.4%, SD: 3.8%, PLA: 0.0%) and rigidity (PNFA: 30.6%, SD: 0.0%, PLA: 10.7%). Calculated positive likelihood ratios indicated bradykinesia (12.1) or rigidity (5.5) was more strongly associated with PNFA than other PPAs. CONCLUSION: These findings suggest that on initial presentation, specific EPS may help distinguish PPA subtypes when linguistic and/or neuroimaging profiles are indistinct. Moreover, EPS could represent a marker of underlying tauopathy, linking clinical presentation to neuropathology in PPA.
BACKGROUND: Extrapyramidal signs (EPS) may vary across 3 major subtypes of primary progressive aphasia (PPA): progressive nonfluent aphasia (PNFA), semantic dementia (SD), and progressive logopenic aphasia (PLA). METHODS: We reviewed initial neurological examinations from a clinical PPA cohort (PNFA = 49, SD = 26, PLA = 28) to determine the prevalence of specific categories of EPS. RESULTS: The presence of any EPS was more common in PNFA (38.8%) and PLA (35.7%) than in SD (3.8%). The PNFA group exhibited the highest prevalence of bradykinesia (PNFA: 22.4%, SD: 3.8%, PLA: 0.0%) and rigidity (PNFA: 30.6%, SD: 0.0%, PLA: 10.7%). Calculated positive likelihood ratios indicated bradykinesia (12.1) or rigidity (5.5) was more strongly associated with PNFA than other PPAs. CONCLUSION: These findings suggest that on initial presentation, specific EPS may help distinguish PPA subtypes when linguistic and/or neuroimaging profiles are indistinct. Moreover, EPS could represent a marker of underlying tauopathy, linking clinical presentation to neuropathology in PPA.
Authors: Maria Luisa Gorno-Tempini; Nina F Dronkers; Katherine P Rankin; Jennifer M Ogar; La Phengrasamy; Howard J Rosen; Julene K Johnson; Michael W Weiner; Bruce L Miller Journal: Ann Neurol Date: 2004-03 Impact factor: 10.422
Authors: I Ferrer; I Hernández; M Boada; A Llorente; M J Rey; A Cardozo; M Ezquerra; B Puig Journal: Acta Neuropathol Date: 2003-08-29 Impact factor: 17.088
Authors: John R Hodges; R Rhys Davies; John H Xuereb; Barney Casey; Melissa Broe; Thomas H Bak; Jillian J Kril; Glenda M Halliday Journal: Ann Neurol Date: 2004-09 Impact factor: 10.422
Authors: Charles R Marshall; Chris J D Hardy; Anna Volkmer; Lucy L Russell; Rebecca L Bond; Phillip D Fletcher; Camilla N Clark; Catherine J Mummery; Jonathan M Schott; Martin N Rossor; Nick C Fox; Sebastian J Crutch; Jonathan D Rohrer; Jason D Warren Journal: J Neurol Date: 2018-02-01 Impact factor: 4.849
Authors: Aitana Sogorb-Esteve; Imogen J Swift; Ione O C Woollacott; Jason D Warren; Henrik Zetterberg; Jonathan D Rohrer Journal: J Neuroinflammation Date: 2021-10-03 Impact factor: 8.322
Authors: Hulya Ulugut; Simone Stek; Lianne E E Wagemans; Roos J Jutten; Maria Antoinette Keulen; Femke H Bouwman; Niels D Prins; Afina W Lemstra; Welmoed Krudop; Charlotte E Teunissen; Bart N M van Berckel; Rik Ossenkoppele; Frederik Barkhof; Wiesje M van der Flier; Philip Scheltens; Yolande A L Pijnenburg Journal: J Neurol Date: 2021-07-03 Impact factor: 4.849